Karthik Ramasamy

Has grant

University of Oxford

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

GRANT TITLE: Tailored monitoring of patients with monoclonal gammopathy to improve early detection of myeloma and monoclonal gammopathy of clinical significance

Open Date: 2021-10-01

Close Date: 2024-09-01

Grant: Close

PREPARE project

Open Date: 2021-06-01

Close Date: 2022-11-01

Grant: Close

Defining risk in smouldering myeloma (SMM) for early detection of multiple myeloma (MM)-

Open Date:

Close Date:

Grant: Close

Investigation of platelet function and cell signalling in multiple myeloma and its treatment

Open Date:

Close Date:

Grant: Close

Oxford Pre-cancerous Lymphoproliferative Disorders: Analysis and Interception study

Open Date:

Close Date:

Articles (20)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (14)

Alexandros Rampotas

Oxford University Hospitals NHS Foundation Trust

UNITED KINGDOM

View details

Kwee Yong

University College London

UNITED KINGDOM

View details

Hermann Einsele

University Hospital Würzburg

GERMANY

View details

Anshul Thakur

University of Oxford

UNITED KINGDOM

View details

Guy Pratt

UNITED KINGDOM

View details

Noopur Raje

Harvard University

UNITED STATES

View details

Yolanda Calle

University of Roehampton

UNITED KINGDOM

View details

Robert Orlowski

Florence Maude Thomas Cancer Research Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

James Dunford

University of Oxford

UNITED KINGDOM

View details

Sagar Lonial

UNITED STATES

View details

Dean Smith

Associate Professor

University of Nottingham

UNITED KINGDOM

View details

Joaquin Martinez-Lopez

SPAIN

View details

Christopher Butler

University of Oxford

UNITED KINGDOM

View details

Adam P Cribbs

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Karthik Ramasamy

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (20)

Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis

Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody

Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper

Challenges in designing and running smouldering myeloma interventional clinical trials

The UK consensus supporting effective introduction of novel treatments for multiple myeloma in the National Health Service

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study

Real‐world treatment patterns in patients initiating third‐line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain

Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.

Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting

INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.

Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.

Editorial: T-cell directed therapies in multiple myeloma.

Flicking the switch in myeloma MRD

Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry

Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.

Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics.

Collaborators (14)

Alexandros Rampotas

Kwee Yong

Hermann Einsele

Anshul Thakur

Guy Pratt

Noopur Raje

Yolanda Calle

Robert Orlowski

James Dunford

Sagar Lonial

Dean Smith

Joaquin Martinez-Lopez

Christopher Butler

Adam P Cribbs

Make your next move.